Syngene International Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 30 Jul 2026

Company page: Syngene International share price, financials & guidance record

Syngene International Limited reported a challenging Q1 FY27 with revenue declining 16% YoY to INR 736 crores and a negative PAT of INR 9 crores, primarily due to the absence of Zoetis offtake and attrition in commoditized research services. The company is undergoing a strategic transition under new leadership, focusing on strengthening CDMO, differentiating discovery services with AI, and expanding clinical research capabilities. Management expects FY27 to be a rebuilding year with a single-digit revenue decline and mid-20s EBITDA margins, aiming for sustainable growth from FY28.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue down 15.8%, net profit down 110.4% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	891	944	1,018	875	911 +2%	917 −3%	1,037 +2%	736 −16%
Expenses	646	660	674	668	711	708	733	645
EBITDA	245	284	344	206	200 −19%	209 −26%	303 −12%	91 −56%
Margin	27%	30%	34%	24%	22%	23%	29%	12%
Other income	17	18	19	18	15	-55	16	12
Interest	13	12	16	12	13	12	12	10
Depreciation	111	109	106	111	117	114	112	112
Profit before tax	137	181	241	101	85 −38%	28 −84%	196 −19%	-19 −119%
Tax rate	23%	27%	24%	14%	21%	47%	25%	-53%
Net profit	106	131	183	87	67 −37%	15 −89%	148 −19%	-9 −110%
EPS	2.64	3.26	4.55	2.15	1.67	0.37	3.67	-0.22

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls